Introduction
Multiple myeloma (MM) is a clonal proliferation of plasma cells in which there is a presence of a paraprotein in the serum or urine in almost all patients. MM is defined by the presence of at least two of the following three criteria: (1) a monoclonal protein in serum and/or urine; (2) lytic bone lesions on X-ray and (3) an excess of plasma cells (>10%) in bone marrow. The incidence of MM in the UK is ∼50 per million population [1] , and MM accounts for 1% of all malignancies and ∼15% of all haematological malignancies [2] . Although there are therapies that can improve survival in MM [3, 4] , it remains an incurable disease, and estimates of median survival vary from 24 months [1] to 44 months [5] . Survival is dependent on the stage of the disease and varies from a median of 62 months in stage 1 disease to 29 months in stage 3 disease [5] . The staging systems used for MM are summarized in Table 1 . Renal failure is an ominous complication of MM, and MM is a relatively common reason for presentation to a tertiary renal unit with unexplained acute kidney injury [6] . However, patients with MM and severe acute kidney injury have been excluded from many previous studies of chemotherapy for myeloma, and their prognosis in the modern era is uncertain.
With the advent of efficacious low toxicity chemotherapy (such as thalidomide and bortezomib [7] ) and new dialysis techniques to remove free light chains [8] , we wished to accurately describe the natural history of this condition in the current era. Our intention in this analysis was to describe the clinical features of patients presenting with severe acute kidney injury (defined by serum creatinine ≥500 µmol/L) due to myeloma and to investigate the factors influencing survival. We therefore reviewed the experience at our institution over the last 20 years, extending a similar analysis previously published [9] to include ∼100 patients and therefore constituting the largest series of such patients.
Subjects and methods
We performed an audit and reviewed the medical records of all patients referred to the Oxford Kidney Unit with a possible diagnosis of myeloma from 1 January 1987 to 31 December 2006 (20 years). Patients were identified from an electronic search of the unit's Proton database and crosschecked with data from previous publications from this dataset [9] . Patients were excluded from the analysis if (1) they did not meet the criteria for severe acute kidney injury (i.e. admission serum creatinine <500 µmol/L, or previous history of chronic renal failure); (2) they had other pathological diagnoses on a kidney biopsy (e.g. amyloid); (3) an alternative explanation was found for their renal failure; or (4) they did not meet the diagnostic criteria for MM [10] . We analysed the presentation and outcome of the remaining 107 patients by reference to hospital records, data held on the Proton database and follow-up from their referring hospital and general practitioner where necessary. Patients were followed until death or, if they remained alive until 31 December 2006.
A diagnosis of MM was made if the patient fulfilled the standard criteria (see above). For the purposes of this analysis, the disease was staged according to Durie and Salmon [11] . Although the recommended staging system is now the International Staging System, β 2 -microglobulin levels were not routinely quantified until 1997 so could not be used (see Table 1 for comparison of staging systems). The urinary paraprotein was not quantified until 1993 and is therefore recorded as detected or not detected. All patients had laboratory and radiological investigations as necessary to exclude other causes of renal failure. All laboratory data presented are that obtained on admission to the Oxford Kidney Unit and therefore reflect any treatment given at the referring hospital (including intravenous fluids, blood transfusion and any hypocalcaemic medication e.g. bisphosphonates). Hypercalcaemia was diagnosed if the serum calcium (corrected for albumin) was >2.90 mmol/L.
The primary outcome of interest was death. The following variables were recorded from the patients' medical notes: age, sex, laboratory values at presentation [serum creatinine, albumin (assayed with bromocresol green), calcium, haemoglobin, white cell count and platelet count], myeloma type and stage and treatment given (plasma exchange and chemotherapy). Information on the cause of death was sought from the patient's hospital medical records and general practitioner. If information was not available from these sources, the death certificate was obtained from the United Kingdom General Registrar's Office.
Continuous variables were converted to categorical variables using internationally accepted cut-off values [5] . Categorical variables were analysed as such. For variables with more than two categories, some categories were combined prior to analysis because of the small numbers in one category (e.g. chemotherapy was collected as none, low dose oral treatment or high dose intravenous treatment, but the small number of patients treated with high dose chemotherapy meant this was analysed in combination with low dose chemotherapy as 'any chemotherapy').
All these variables were then analysed for their association with survival, and hazard ratios for death rate from all causes were calculated using Cox regression. Further, time-dependent Cox regression analyses were performed using recovery of renal function as a time-dependent explanatory variable. Significance tests were two-sided. The analyses presented in this paper were also performed using continuous variables as such, and this did not materially affect the results (data not shown).
The STATA statistics package (STATA Corp., College Station, TX, USA, Version 9.2) was used for all statistical analyses.
Results

Presentation and initial management
The baseline demographic, laboratory, diagnostic and treatment data of the 107 patients are shown in Table 2 , and the distribution of patients by year of referral are shown in Figure 1 . The mean age was 67 years, with an almost 2:1 ratio of males to females. The mean serum creatinine concentration at presentation was 929 µmol/L (range 501-2600 µmol/L). Just under half of the patients (44%) had light chain myeloma and over three quarters of the patients (77%) had documented Bence Jones proteinuria. Two-thirds of the patients had myeloma diagnosed after their admission with acute kidney injury; of the third who were diagnosed with myeloma prior to admission, the median delay between myeloma diagnosis and referral with acute kidney injury was 48 days. Seventy-eight percent of patients had myeloma diagnosed within a period of 30 days before or 30 days after their admission with acute kidney injury. Precipitants (e.g. hypercalcaemia, use of non-steroidal anti-inflammatories) which may have contributed to the onset of acute kidney injury were identified among 37 patients (35%) and are summarized in Table 3 . Only a minority of patients (14%) had a renal biopsy performed, either because it was considered unlikely to change the patient management in the majority of cases, or because the patient was too unwell to undergo the procedure. The most common finding was cast nephropathy (10/15), but other findings included acute tubular necrosis and acute interstitial nephritis.
The decision of how to treat the MM was made by the haematologists who reviewed all cases during the index admission. Many different chemotherapy regimens were used during the 20 years. No patient in this analysis received thalidomide (or its derivatives) or bortezomib. Ten (9%) patients were not given any chemotherapy, usually because of severe comorbidity. Because many patients were referred back to their local hospital for ongoing haematological management, we do not have complete data on subsequent management, including how many patients went on to receive an autologous stem cell transplant and what the haematological response was to the treatment given. A total of 88 patients (82%) were dialysed during their index admission at the discretion of the managing nephrologist, and the first modality was haemodialysis or haemofiltration in all patients. There were no significant differences in the baseline characteristics of those patients dialysed compared to those not dialysed during their index admission (see Table 2 ). Of these, 15 (17%) patients recovered sufficient renal function to come off dialysis, whereas the remaining 73 patients either died or were established on maintenance dialysis. Nineteen (18%) patients were not dialysed during their index admission; 2 of these subsequently developed end-stage renal failure requiring renal replacement therapy. Therefore, 32 (30%) patients achieved independent renal function following their acute kidney injury.
Mortality
The median survival for the entire group was 10.2 months, (interquartile range 2-21 months; see Figure 2 ). The causes of death are summarized in Table 4 ; over half of all deaths were attributed to the underlying myeloma. The results of the unadjusted analysis in which each baseline variable was considered separately, and of the adjusted analysis, in which they were all considered simultaneously, are broadly similar (see Table 5 ). A serum albumin ≥35 g/dL was associated with improved survival in both analyses (unadjusted hazard ratio 0.62; 95% CI: 0.40-0.96; P = 0.03), and the strength of the association was increased in the multiple regression analysis (hazard ratio 0.56; 95% CI: 0.35-0.91; P = 0.02); see Figure 3 ). This is consistent with the current standard prognostic score for all cases of myeloma, the International Scoring System [5] .
Use of chemotherapy was also strongly associated with survival in both unadjusted and adjusted analyses (adjusted hazard ratio 0.20; 95% CI: 0.08-0.47; P < 0.001; see Figure 4 ). This is not unexpected, although none of the proven therapies in myeloma have been rigorously tested by randomized controlled trials in patients with advanced renal failure.
The stage of disease was not significantly associated with survival in this cohort even in the unadjusted analysis (unadjusted hazard ratio 0.98; 95% CI: 0.63-1.52) for stage 3 versus stage 1 or 2 disease. Albumin (which was associated with survival in this analysis) is now used in the International Scoring System (and is a marker of disease stage in this system), whereas it was not used by the Durie and Salmon staging system which this analysis has used.
Effect of recovery of renal function
Time-dependent regression analyses showed that recovery of renal function was associated with a reduced risk of death in both unadjusted and adjusted analyses. This analysis was performed both for the entire study population and for the subset that presented with dialysis-dependent acute kidney injury (see Table 6 ). In the 88 patients who required dialysis at presentation, the risk of death was reduced significantly in patients who recovered renal function to become dialysis independent (see Figure 5 ). In the whole study population, patients not on dialysis (i.e. who never required it or who had previously required it but had recovered renal function) had better survival than patients on dialysis.
Discussion
Renal failure is a common complication of MM, but estimates of its incidence at presentation of MM depend strongly upon the definition of renal failure. In a cohort of 1353 incident cases of MM, 31% had renal failure defined by a serum creatinine >130 µmol/L, but this increased to 49% if renal failure was defined by estimated glomerular filtration rate (eGFR) instead [12] . Although impaired renal function has been a marker of poor prognosis in some unadjusted analyses [13] , it is no longer so after adjustment for tumour burden [14] , i.e. patients with renal failure tend to have large tumour loads. This concurs with the description of the International Scoring System for MM that identified raised creatinine (>2 mg/dL) as a weak discriminator of prognosis in a multiple regression analysis [5] , as most patients with renal failure have stage 3 disease. Severe renal failure (serum creatinine >500 µmol/L) occurs in ∼5% of patients with MM [13, 14] ; some studies have suggested that recovery of renal function (and hence avoidance of maintenance dialysis) is associated with improved survival [15] , but they included few patients. Acute kidney injury has a high risk of mortality, and myeloma is an incurable haematological malignancy. The combination of these two diagnoses has long been known to carry a poor prognosis, and this analysis confirms that the majority of patients will have died by 1 year after their presentation with acute kidney injury. The median survival in this study was 10.2 months, and this has not changed appreciably since an earlier publication that included some of the patients included in this analysis [9] . Furthermore, the year of presentation was not associated with a difference in survival. This may be due to a change in the type of patients referred to the tertiary Oxford Kidney Unit over time. The numbers of patients on renal replacement therapy in the UK has changed from ∼12 500 in 1986 to ∼40 000 in 2006 [16] , which is due to many reasons including a larger elderly population (who are more likely to develop end-stage renal disease) and also increased awareness of the disease and availability of the treatment leading to increased referral to specialist services. This is likely to affect not only the chronic renal failure population, but also patients with acute kidney injury. It is probable (although not possible to prove from the available data) that patients who would have been considered too old or sick for referral to a tertiary centre in the 1980s are now more likely to be referred. However, even after adjustment for established prognostic markers (such as albumin), year of presentation is still not associated with survival. Furthermore, the average age of patients presenting to the Oxford Kidney Unit was not different in the two decades as covered by this analysis (mean age of patients presenting from 1987 to 1996 was 67 years compared to 66 years for patients presenting from 1997 to 2006). Age itself was not associated with survival, and therefore, age should not be used as a criterion for referral by itself. This is supported by a similar finding from a larger analysis of the general dialysis population from one region of the UK [17] .
Serum albumin was significantly associated with survival in both unadjusted and adjusted analyses. This is consistent with an analysis of a larger population with MM (including the whole spectrum of renal function) [5] , and it is useful to demonstrate that it still carries a prognostic value in the population with severe acute kidney injury. The other component of the International Scoring System, β 2 -microglobulin, was not measured in all patients in this analysis, so could not be included in the model.
Treatment with chemotherapy was strongly associated with improved survival. This is perhaps to be expected, although it is not clear whether it was the chemotherapy that improved survival, or whether other factors that led to the decision not to treat with chemotherapy caused the poorer survival in the untreated cohort. This analysis has corrected for many of the objective factors that could have led to such a decision, but it is likely that there are other factors that operate in the decision of whether to treat or not that cannot be controlled for. However, the relatively poor survival of patients with end-stage renal failure and MM has certainly raised questions about the utility of treating such patients and a degree of 'therapeutic nihilism', and the present result is encouraging in that it suggests that treating such patients can be worthwhile. Autologous stem cell transplantation is the treatment of choice if the patient is fit enough [3] , but this generally requires high-dose melphalan treatment (the risks of which increase significantly in patients with impaired renal function), so patients with severe renal failure are unlikely to receive such treatments.
Until recently, no chemotherapy regimen had been shown to improve survival in patients with myeloma if they were not a candidate for transplantation [18] . However, new agents (i.e. bortezomib and thalidomide) are now available which have shown survival benefit in such patients [7, 19, 20] , although no patient in the current analysis received such therapy. There are trials in progress of such regimens that include patients with advanced renal failure [21] , although very few such patients were recruited into the published trials [19, 20] . The effectiveness of chemotherapy appears to be vital in the success of these strategies [8] , which demands that randomized trials are done with sufficient power to demonstrate both safety and efficacy of such therapies. These trials are vital if the dismal prognosis of this patient population is to be improved, and until then clinicians will continue to extrapolate data from other populations to guide their therapeutic decisions in this difficult group of patients.
The effect of independent (i.e. not dialysis dependent) renal function was striking and persisted after adjustment for albumin and use of chemotherapy. This has been shown by previous analyses [15, 22] , although they only included 34 and 40 patients, respectively. It is likely that the relationship between independent renal function and overall survival is confounded by the response of the underlying plasma cell clone to chemotherapy, i.e. those patients whose myeloma responded to chemotherapy were both more likely to regain independent renal function (as the renal insult was removed) and survive longer as their myeloma responds to therapy. Unfortunately, we could not study the haematological response to chemotherapy because many patients were treated at their local hospital and we did not have access to their records. However, our analysis does highlight the importance of trials of therapies that attempt to restore independent renal function, as only these will be able to assess the benefit of such treatments independently from any haematological effect of chemotherapy.
Plasma exchange is the most widely used therapy used to attempt to salvage renal function. There have been three trials of plasma exchange in this setting [23] [24] [25] , but all have been criticized. In the study by Zuccheli et al., there was a systematic difference between the groups in that the plasma exchange group received haemodialysis, whereas the control group received peritoneal dialysis [23] . The study by Johnson et al. was small, and the two groups were imbalanced for prognostic baseline variables [24] . The more recent study by Clark et al. is the largest completed trial of plasma exchange in advanced kidney disease, but it still randomized only 104 patients [25] . This trial has been criticized for including an eGFR <30 mL/min/1.73 m 2 in its primary outcome (along with death and dialysis) which many nephrologists would view as a success, as it may allow patients to remain independent of dialysis for the rest of their life [22] . However, with only 154 patients recruited into completed randomized trials of plasma exchange, uncertainty remains about its utility in this situation. It is, therefore, unfortunate that the MyEloma Renal Impairment Trial (MERIT) [26] has not succeeded in recruiting the required number of patients. MERIT planned to recruit 286 patients, but has closed recruitment after randomizing ∼90 patients. Plasma exchange may not be efficient enough to remove serum free light chains to allow the kidney to recover from the insult of excessive glomerular filtration of free light chains [27] . The excess saturates the clearance mechanisms in the proximal tubule, and the resulting overflow into the distal tubule precipitates with the Tamm-Horsfall protein and causes tubular obstruction and an inflammatory reaction [28] . High permeability cut-off dialysis has recently been suggested as an alternative strategy for light chain removal, and mathematical models suggest that it would be superior, especially in conjunction with highly effective chemotherapy [8] . An international randomized controlled trial is underway [29] , although the small sample size (n = 90) may limit the reliability of any conclusions that can be drawn. The present retrospective study did not demonstrate any benefit of plasma exchange, but this is no substitute for randomized evidence as discussed above.
In summary, severe acute kidney injury (defined by serum creatinine ≥500 µmol/L) still has a poor prognosis in patients with myeloma, with a median survival of 10.2 months that has not changed over the past decade. The use of chemotherapy is associated with improved survival, although further trials are needed to establish the utility of novel chemotherapy strategies in this population. Prognostic markers such as albumin from the myeloma population with preserved renal function also appear to apply to this subgroup, and the recovery of independent renal function is also associated with improved survival. Further studies are required to define whether this is simply due to the response of the plasma cell clone to chemotherapy, or whether therapies that solely aim to preserve or restore renal function provide additional benefit. New therapies aimed at both the plasma cell and the recovery of renal function are now available, and this is an exciting time for nephrologists with an interest in myeloma; future studies will tell us whether we can at last improve the prognosis for this group of patients.
